Epjevy: Withdrawal of the marketing authorisation application
Table of contents
Overview
On 7 February 2019, CTI Life Sciences Limited officially notified the Committee for Medicinal Products for Human Use (CHMP) that it wishes to withdraw its application for a marketing authorisation for Epjevy, for treating symptoms of myelofibrosis in patients with severe thrombocytopenia.
Key facts
Name |
Epjevy |
Product number |
EMEA/H/C/004793 |
Date of withdrawal |
07/02/2019 |
Company making the application | |
Withdrawal type |
Initial authorisation |
Related information on withdrawals
A question-and-answer (Q&A) document provides a summary of the CHMP's evaluation of the medicine at the time of the withdrawal of the application, and includes a link to the company's formal withdrawal letter.
An assessment report is published when the application is withdrawn after the first stage of the CHMP's evaluation is completed ('day 120').